Subst. for f	orm 1449/I	то		Cor	mnloto	if Known	
				Application Number			
		DISCLOSURE STA	TEMENT BY		iling Date 02/27/2004		
APPLICA		s as necessary)		First Named Inventor			
(Ose as in	any sneed	s as necessary;			Oom O. Dabian		
				Art Unit		1617	
Sheet 1 of				Examiner Name		Kendra D. Carter	
Sheet		1 of	2	Docket Number	L	068911-0074	
			U.S. PATENT	DOCUMENTS			
Examiner Initials	Cite No.	Document Number Number-Kind Code ²	Publication Da MM-DD-YYY			Pages, Columns, Line Where Relevant Passage Relevant Figures Appe	es or
			FOREIGN PATE	NT DOCUMENTS			
Examiner Initials	Cite No 1	Document Number	Publication Dat	a Name of Patentee	Name of Patentee or		
		Country Code ³ –Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Giled Document		Where Relevant Passages or Relevant Figures Appear	Lo
/K.C./	B23	DE1901277	01/10/1969	Partipharm			
			OT	HER	•••••		<u> </u>
Examiner	Cite No.1	Linguido nomo efithe a					,
Initials	GRE INU.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazen, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
/K.C./	C104	Examination Report from related EP Application No. 05723839.6, dated 1/22/10, 6 pages.					
/K.C./	C105	Bolick, et al., "Lisofylline, a Novel Anti-inflammatory Compound, Protects Mesangial Cells From Hyperglycemia – and Angiotensin 11-Mediated Extracellular Matrix Deposition", ENDOCRINOLOGY, Vol. 144, No. 12, Dec.2003, pages 5227-5231.					
/K.C./	C106	Abdel-Salam, et al., "The Anti-Inflammatory Effects of the Phosphodiesterase Inhibitor Pentoxifylline in the Rat", PHARMACOLOGICAL RESEARCH, ENGLAND, Vol. 47, No. 4, April 2003, pages 311-340.					
Examiner	1	/Kendra Carte	er/	Date		12/15/2010	

Signature Considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's to place a check mark here if English Lenguise Translation is attached. This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U S C. 122 and 37 CFR 1.19. Send to Commissioner for Patients, P.O. Box 1450, Mexandria, IAV 2231301450